Identification of a pharmacological approach to reduce ACE2 expression and development of an in vitro COVID-19 viral entry model
Yukinori Endo(United States Department of Health and Human Services), Wen Jin Wu(Center for Drug Evaluation and Research)
Cited by 5
Related Papers
VPS34 regulates TSC1/TSC2 heterodimer to mediate RheB and mTORC1/S6K1 activation and cellular transformation
|Oncotarget|2016|28
Atezolizumab Induces Necroptosis and Contributes to Hepatotoxicity of Human Hepatocytes
|International Journal of Molecular Sciences|2023|16
Structural and functional characterization of IgG- and non-IgG-based T-cell-engaging bispecific antibodies
|Frontiers in Immunology|2024|12